

Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

LN-308

RRID:CVCL_0394

Type: Cell Line

Proper Citation

RRID:CVCL_0394

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0394

Proper Citation: RRID:CVCL_0394

Description: Cell line LN-308 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Astrocytoma

Defining Citation: [PMID:2990147](#), [PMID:7693337](#), [PMID:9842975](#), [PMID:10416987](#), [PMID:11351043](#), [PMID:14614447](#), [PMID:14655754](#), [PMID:17595512](#), [PMID:20504876](#), [PMID:20593219](#), [PMID:22570425](#), [PMID:25984343](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LN-308

Synonyms: LN 308, LN308, LNZ-308, LNZ 308, LNZ308, LN-Z308

Cross References: BTO:BTO_0004457, EFO:EFO_0022714, MCCL:MCC:0000289, BioGRID_ORCS_Cell_line:406, BioSample:SAMN10988416, cancercellines:CVCL_0394, Cell_Model_Passport:SIDM00682, Cosmic:849863, Cosmic:2367499, Cosmic:2516023, DepMap:ACH-000760, IARC_TP53:22502, Pharmacodb:LNZ308_852_2019, PRIDE:PXD008984, Wikidata:Q54902775

ID: CVCL_0394

Record Creation Time: 20220427T220731+0000

Record Last Update: 20260920T004357+0000

Ratings and Alerts

No rating or validation information has been found for LN-308.

No alerts have been found for LN-308.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

DeAngelo SL, et al. (2025) Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer. Cancer research, 85(15), 2788.

Sallbach J, et al. (2024) The cell cycle inhibitor p21CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 181, 117634.

Merk DJ, et al. (2024) Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. Genome biology, 25(1), 301.

Jane EP, et al. (2023) Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas. Molecular oncology, 17(9), 1821.

Nguyen TT, et al. (2023) Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA repair protein MPG. Molecular oncology, 17(9), 1744.

Hanisch D, et al. (2022) Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression. Cell death & disease, 13(4), 293.

Zhang M, et al. (2020) Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma. Frontiers in genetics, 11, 441.

Berberich A, et al. (2020) LAPTM5-CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance. Frontiers in oncology, 10, 747.

Zhang M, et al. (2020) Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. *Frontiers in genetics*, 11, 363.

Jameson NM, et al. (2019) Intron 1-Mediated Regulation of EGFR Expression in EGFR-Dependent Malignancies Is Mediated by AP-1 and BET Proteins. *Molecular cancer research : MCR*, 17(11), 2208.

Aasland D, et al. (2019) Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF- κ B. *Cancer research*, 79(1), 99.

Nguyen CDL, et al. (2019) A sensitive and simple targeted proteomics approach to quantify transcription factor and membrane proteins of the unfolded protein response pathway in glioblastoma cells. *Scientific reports*, 9(1), 8836.

Happold C, et al. (2018) Transcriptional control of O6 -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. *Journal of neurochemistry*, 144(6), 780.